920
Views
20
CrossRef citations to date
0
Altmetric
Laboratory Study

Renoprotection of Kolaviron against benzo (A) pyrene-induced renal toxicity in rats

, , , &
Pages 497-504 | Received 07 Sep 2014, Accepted 11 Dec 2014, Published online: 23 Jan 2015
 

Abstract

Benzo(a)pyrene (B[a]P), a polycyclic aromatic hydrocarbon generally formed from incomplete combustion of organic matter, reportedly causes renal injury and elicits a nephropathic response. The present study investigated the modulatory effect of Kolaviron, an isolated bioflavonoid from the seed of Garcinia kola, on renal toxicity induced by B[a]P in Wistar rats. Benzo[a]pyrene was administered at a dose of 10 mg/kg alone or in combination with Kolaviron at 100 and 200 mg/kg for 15 d. Administration of B[a]P alone resulted in significant increase in plasma levels of urea and creatinine in the treated rats. Moreover, B[a]P exposure significantly decreased the activities of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and glutathione-s-transferase (GST) as well as glutathione (GSH) level in the kidneys of treated rats. Conversely, myeloperoxidase (MPO) activity, hydrogen peroxide (H2O2) and malondialdehyde (MDA) levels were markedly elevated in kidneys of B[a]P-treated rats compared with control. Further, B[a]P exposure significantly decreased the circulatory concentrations of triiodothyronine (T3) and T3/T4 ratio without affecting thyroxine (T4) in the treated rats. Light microscopy revealed tubular lumen with numerous protein casts in kidneys of rats exposed to B[a]P alone. Kolaviron co-treatment significantly improved the renal antioxidant status, thyroid gland function and restored the renal histology, thus demonstrating the protective effect of Kolaviron in B[a]P-treated rats. Dietary inclusion of Kolaviron could exert protective effects against renal toxicity resulting from B[a]P exposure.

Declaration of interest

The authors report no conflicts of interest. This research was done without specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.